Altimmune Statistics

Total Valuation

Altimmune has a market cap or net worth of $586.78 million. The enterprise value is $449.17 million.

Market Cap	586.78M
Enterprise Value	449.17M

Important Dates

The last earnings date was Tuesday, November 12, 2024, before market open.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Altimmune has 71.12 million shares outstanding. The number of shares has increased by 32.62% in one year.

Current Share Class	71.12M
Shares Outstanding	71.12M
Shares Change (YoY)	+32.62%
Shares Change (QoQ)	+0.23%
Owned by Insiders (%)	0.74%
Owned by Institutions (%)	56.11%
Float	70.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	4.40
P/TBV Ratio	4.40
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	8,637.91
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 16.87, with a Debt / Equity ratio of 0.01.

Current Ratio	16.87
Quick Ratio	16.52
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-9,951.00

Financial Efficiency

Return on equity (ROE) is -72.96% and return on invested capital (ROIC) is -43.44%.

Return on Equity (ROE)	-72.96%
Return on Assets (ROA)	-39.56%
Return on Capital (ROIC)	-43.44%
Revenue Per Employee	$881
Profits Per Employee	-$1.75M
Employee Count	59
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +1.10% in the last 52 weeks. The beta is 0.15, so Altimmune's price volatility has been lower than the market average.

Beta (5Y)	0.15
52-Week Price Change	+1.10%
50-Day Moving Average	7.88
200-Day Moving Average	7.43
Relative Strength Index (RSI)	48.05
Average Volume (20 Days)	3,364,954

Short Selling Information

The latest short interest is 23.43 million, so 32.95% of the outstanding shares have been sold short.

Short Interest	23.43M
Short Previous Month	22.84M
Short % of Shares Out	32.95%
Short % of Float	33.20%
Short Ratio (days to cover)	5.81

Income Statement

In the last 12 months, Altimmune had revenue of $52,000 and -$103.52 million in losses. Loss per share was -$1.53.

Revenue	52,000
Gross Profit	-79.30M
Operating Income	-99.51M
Pretax Income	-101.35M
Net Income	-103.52M
EBITDA	-99.19M
EBIT	-99.51M
Loss Per Share	-$1.53

Full Income Statement

Balance Sheet

The company has $139.38 million in cash and $1.77 million in debt, giving a net cash position of $137.61 million or $1.93 per share.

Cash & Cash Equivalents	139.38M
Total Debt	1.77M
Net Cash	137.61M
Net Cash Per Share	$1.93
Equity (Book Value)	133.38M
Book Value Per Share	1.88
Working Capital	137.12M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-78.12M
Capital Expenditures	n/a
Free Cash Flow	-78.12M
FCF Per Share	-$1.10

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-191,365.38%
Pretax Margin	-199,076.92%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Altimmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-32.62%
Shareholder Yield	-32.62%
Earnings Yield	-17.64%
FCF Yield	-13.31%

Dividend Details

Analyst Forecast

The average price target for Altimmune is $20.00, which is 142.42% higher than the current price. The consensus rating is "Buy".

Price Target	$20.00
Price Target Difference	142.42%
Analyst Consensus	Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	227.51%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on September 14, 2018. It was a reverse split with a ratio of 0.0333333:1.

Last Split Date	Sep 14, 2018
Split Type	Reverse
Split Ratio	0.0333333:1

Scores

Altimmune has an Altman Z-Score of 12.19 and a Piotroski F-Score of 2.

Altman Z-Score	12.19
Piotroski F-Score	2